vialroom

#retatrutide 2025-12-04

Thursday53 messages10 participantstimes are UTC
Highlights from this day
  • tga_notice — the phase 2 weight result was larger than what the earlier agonists reported, in a smaller shorter trial, i have it written down somewhere 22:16
  • escalation_anxiety — no idea whether the heart rate settles for everyone, mine did and one log isnt data 22:41
  • pinch_not_stretch — how do people square the research use only framing with logging their own use 22:50
  • revoked_ro — is there any long term safety data at all or is it phase 2 and hope 22:52
  • warsaw_vial — research use only is on every vial and i treat it as exactly that, nobody here is prescribing 23:12
WV

TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule

watching my heart rate

came off at 9 weeks because my resting rate stayed elevated and i didnt like it

RR

buying this is a completely different risk conversation from the licensed compounds and that gets said too rarely

unrelated but does the energy expenditure claim show up as anything you can feel

TN

the phase 2 weight result was larger than what the earlier agonists reported, in a smaller shorter trial, i have it written down somewhere

💀13

does the glucagon arm explain the heart rate or is that unrelated

WV

triple agonist meaning GLP-1, GIP and glucagon, have i got that right

my resting rate went up 3 bpm in the first month and came back most of the way by month 2

SS

is the phase 2 dosing anywhere near what people here run

triple agonist yeah

update on the earlier thing the half life supports weekly dosing and thats what ive done from the start

quick one phase 2 was still trending at the end which is why the phase 3 readout matters more than usual

VL

the glucagon arm is the mechanistic story for extra energy expenditure and its still a story to me

SS

reconstituted the 30 vial to 5mg/ml specifically so i could take 2 without measuring crumbs
PeptideMeter came back 99 on one lot and 99.2 on the next from the same MKM, both fine

no idea whether the heart rate settles for everyone, mine did and one log isnt data

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

nobody should read my log as a plan, im recording what i did and thats all it is

low and slow

stepping in 0.5 increments instead of doubling is the only thing i would change if i started again

RS

held at 2.4 for 6 months and it never plateaued for me, which i cant explain

PN

how do people square the research use only framing with logging their own use

😂15📈7🧪2
RR

is there any long term safety data at all or is it phase 2 and hope

🧪15📉7

quick one low and slow here means smaller steps than i ever used on tirzepatide, thats the received wisdom

SS

my resting heart rate is up about 2 bpm, did that settle for anyone

smaller steps here

EA

the honest position is this has less human evidence behind it than anything else discussed here

SS

blood pressure stayed flat for me while heart rate moved, which i didnt expect

🤝2

glucagon is the new bit

PN

appetite suppression at 5 was stronger than my tirzepatide experience at a comparable point

i log resting heart rate every morning because of this and its the one number i actually watch, i have it written down somewhere

[edited]

PeptideMeter came back 97.4 on one lot and 99 on the next from the same JEEP, both fine, i could be wrong

WV

research use only is on every vial and i treat it as exactly that, nobody here is prescribing

🤝14

*that should say weekly

triple agonist, GLP-1 and GIP and glucagon. the glucagon arm is the part with no long history

anyone tracking blood pressure alongside the heart rate

SS

the heart rate thing is real enough that i mention it whenever someone asks about starting

WV

i was wrong to call the heart rate a non issue last year, enough people logged it that i changed my mind
phase 2 was still trending at the end which is why the phase 3 readout matters more than usual

PN

slightly off topic but why does everyone insist on smaller steps here than on the other two

*Medutest not the other one

WV

back after 26 months, has anything actually been published since

the purity spread across lots worries me more than the molecule does, for what its worth

PN

phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan

💀3
PN

GI was about the same as tirzepatide for me, the difference was how fast it arrived

[edited]
Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.